Topics

Talazoparib Approaches EU Approval for BRCA-Mutated, HER2-Negative Breast Cancer

17:27 EDT 29 Apr 2019 | OncLive

The European Medicines Agency's Committee for Medicinal Products for Human Use has backed approval of talazoparib (Talzenna) for adult patients with HER2-negative locally advanced or metastatic breast cancer harboring germline BRCA1/2 mutations.

Original Article: Talazoparib Approaches EU Approval for BRCA-Mutated, HER2-Negative Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Talazoparib Approaches EU Approval for BRCA-Mutated, HER2-Negative Breast Cancer"

Quick Search

Relevant Topic

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...